We use cookies for a better user experience. Read our Privacy Policy
I Agree
Thalassemia Treatment Market
Thalassemia Treatment Market: Snapshot
The global thalassemia treatment market is pegged to gain significant amount in the form of revenues during the forecast period of 2018 to 2026. One of the major reasons for this prodigious growth is considerable growth in the number of altered thalassemia genes in people from all worldwide locations. Thalassemia is a genetic disorder related to blood. In this disease, patient’s body is not able to produce normal hemoglobin and manufactures a huge number of abnormal red blood cells, which are continuously destroyed. As a result, an individual becomes anemic.
The segmentation of the global thalassemia treatment market is performed on the basis of treatment type and region. Among all treatment options, blood transfusion and chelation therapy are the most popular options used in treating thalassemia patients. Key reasons for this popularity are the cost-effectiveness and easy accessibility than bone marrow transplantation.
The global market for thalassemia treatment is witnessing stupendous growth avenues due to significant growth in the number of blood transfusion and chelation therapy treatments. Apart from this, increased number of bone marrow transplants, rise in number of spleen surgeries, and increased investments in research and development activities are some of the key factors stimulating the growth of the global thalassemia treatment market.
The global thalassemia treatment market is fairly fragmented in nature. Presence of many well-established enterprises connotes high competitive landscape of the market for thalassemia treatment. To lead in this competition, companies working in the thalassemia treatment market are executing various strategic moves such as collaborations and partnerships. Apart from this, they are focused on incorporation of technological advancements in their work processes. A case in point here is recent collaboration announcement by Novartis and Microsoft. Through this collaboration, Microsoft will help Novartis in its medicine transformation using artificial intelligence. Thus, this collaboration will impact positively on the growth of the global thalassemia treatment market in the upcoming period.
Thalassemia Treatment Market - Snapshot
The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy treatments, high number of bone marrow transplants, increase in number of spleen surgeries, and surge in R&D expenditure.
Thalassemia is a genetic blood disorder which produces abnormal hemoglobin in the body. This genetic blood disorder leads to the formation of a large number of red blood cells that are continuously destroyed, which further leads to anemia. The two types of proteins present in the blood of thalassemia patients are alpha globin and beta globin. Alpha thalassemia occurs primarily in people living in Southeast Asia, the Middle East, China, and Africa. Beta thalassemia occurs in people in the Mediterranean origin, and to a lesser extent in people in China, other Asians, and African Americans. Chelation therapy and blood transfusion are the most common treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion technique for purifying blood increase the possibility of curing thalassemia patients.
Blood transfusion helps patients suffering from alpha thalassemia or beta thalassemia. The transfusion treatment procedure improves overall operational efficiency. High prevalence and incidence rates of thalassemia and rise in number of stem cell transplantations among the global population have resulted in increase in patient flow to private clinics and hospitals. These factors are projected to drive demand for blood transfusion procedure for thalassemia treatment in the near future. Moreover, advancements in gene therapy such as gene editing, stem cell therapy, and proliferation of new drugs for thalassemia treatment are anticipated to fuel the growth of the global thalassemia treatment market from 2018 to 2026.
The global thalassemia treatment market has been segmented based on treatment type and region. In terms of treatment type, the global market has been categorized into blood transfusion, chelating therapy, bone marrow transplant, and others. The chelation therapy segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at an exponential growth rate during the forecast period. Blood transfusion offers several advantages over bone marrow transplantation such as low cost of treatment. Hence, blood transfusion is gaining popularity among thalassemia patients.
Geographically, the global thalassemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to lose market share between 2018 and 2026. The market in North America is primarily driven by rapidly increasing immigrant population from tropical regions, growing number of population with thalassemia carrier gene, and rise in birth rates due to variation of genes among the population in the U.S. Moreover, increase in same community marriage practices and high birth rate of alpha thalassemia patients have been observed in Asia Pacific. This is projected to increase adoption of blood transfusion and chelation therapy treatments during the forecast period. Middle East & Africa is projected to be the fastest growing market for thalassemia treatment during the forecast period. Rest of Middle East & Africa dominated the thalassemia treatment market in the region, while the market in GCC Countries is estimated to expand at an exponential CAGR during the forecast period.
Companies such as bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) accounted for the major share of the global thalassemia treatment market in 2016. Celgene Corporation has provided over 525,000 patients with the prescribed Luspatercept medicine. In 2017, the company accelerated 160 trials in approximately 60 indications and more than 25 new molecules have entered preclinical or phase 1 development. Other global players operating in the market include Incyte Corporation, Kiadis Pharma, Gamida Cell, and Bellicum Pharmaceuticals. Companies are adopting the strategy of acquisition and collaboration with parallel companies to improve and strengthen geographic presence in the international market. Moreover, the partnership agreement with companies is expected to increase in number of clinical trials for thalassemia in the near future.
The global thalassemia treatment market has been segmented as given below:
|
Treatment Type |
|
|
Region |
|
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Thalassemia Treatment Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Pipeline of Thalassemia Treatment
4.8. Prevalence & Demography - Thalassemia Disease - by Region/Country
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9. Cost of Treatment-By Region/Country
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.9.5. Middle East & Africa
4.10. Prevalent Treatment Regimens - By Country/Region
4.10.1. Asia Pacific
4.10.2. Middle East & Africa
4.11. List of Major Hospitals for Thalassemia Treatment - By Region/ Country/State
4.11.1. North America
4.11.2. Europe
4.11.3. Asia Pacific
4.11.4. Latin America
4.11.5. Middle East & Africa
4.12. Regulatory Scenario, by Region
4.12.1. North America
4.12.2. Europe
4.12.3. Asia Pacific
Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast, by Treatment Type, 2016–2026
5.3.1. Blood Transfusion
5.3.2. Chelation Therapy
5.3.3. Bone Marrow Transplant
5.3.4. Others
5.4. Market Attractiveness, by Treatment Type
Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
6.1. Key Findings
6.2. Market Value Forecast, by Region
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3. Market Attractiveness, by Country/Region
Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.2. Market Value Forecast, by Treatment Type, 2016–2026
7.2.1. Blood Transfusion
7.2.2. Chelation Therapy
7.2.3. Bone Marrow Transplant
7.2.4. Others
7.3. Market Value Forecast, by Country, 2016–2026
7.3.1. U.S.
7.3.2. Canada
7.4. Market Attractiveness Analysis
7.4.1. By Treatment Type
7.4.2. By Country
Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2016–2026
8.2.1. Blood Transfusion
8.2.2. Chelation Therapy
8.2.3. Bone Marrow Transplant
8.2.4. Others
8.3. Market Value Forecast, by Country/Sub-region, 2016–2026
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country/Sub-region
Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2016–2026
9.2.1. Blood Transfusion
9.2.2. Chelation Therapy
9.2.3. Bone Marrow Transplant
9.2.4. Others
9.3. Market Value Forecast, by Country/Sub-region, 2016–2026
9.3.1. China
9.3.2. India
9.3.3. ASEAN countries
9.3.4. Rest of Asia Pacific
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region
Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast, by Treatment Type, 2016–2026
10.2.1. Blood Transfusion
10.2.2. Chelation Therapy
10.2.3. Bone Marrow Transplant
10.2.4. Others
10.3.Market Value Forecast, by Country/Sub-region, 2016–2026
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4.Market Attractiveness Analysis
10.4.1. By Treatment Type
10.4.2. By Country/Sub-region
Chapter 11. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2016–2026
11.2.1. Blood Transfusion
11.2.2. Chelation Therapy
11.2.3. Bone Marrow Transplant
11.2.4. Others
11.3.Market Value Forecast, by Country/Sub-region, 2016–2026
11.3.1. GCC countries
11.3.2. South Africa
11.3.3. Rest of Middle East & Africa
11.4.Market Attractiveness Analysis
11.4.1. By Treatment Type
11.4.2. By Country/Sub-region
Chapter 12. Competition Landscape
12.1.Market Player - Market Presence (2017)
12.1.1. Current Offerings
12.1.2. Strategy
12.2.Company Profiles
12.2.1. bluebird bio, Inc.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. SWOT Analysis
12.2.1.4. Financial Overview
12.2.1.5. Strategic Overview
12.2.2. Acceleron Pharma, Inc.
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. SWOT Analysis
12.2.2.4. Financial Overview
12.2.2.5. Strategic Overview
12.2.3. Novartis AG
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. SWOT Analysis
12.2.3.4. Financial Overview
12.2.3.5. Strategic Overview
12.2.4. Celgene Corporation
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. SWOT Analysis
12.2.4.4. Financial Overview
12.2.4.5. Strategic Overview
12.2.5. Shire Plc. (Takeda Pharmaceuticals)
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. SWOT Analysis
12.2.5.4. Financial Overview
12.2.5.5. Strategic Overview
12.2.6. Incyte Corporation
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. SWOT Analysis
12.2.6.4. Financial Overview
12.2.6.5. Strategic Overview
12.2.7. Kiadis Pharma
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. SWOT Analysis
12.2.7.4. Financial Overview
12.2.7.5. Strategic Overview
12.2.8. Bellicum Pharmaceuticals
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. SWOT Analysis
12.2.8.4. Financial Overview
12.2.8.5. Strategic Overview
12.2.9. GlaxoSmithKline plc
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. SWOT Analysis
12.2.9.4. Financial Overview
12.2.9.5. Strategic Overview
12.2.10. Others
List of Tables
Table 01: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 02: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 03: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 04: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 05: U.S. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 06: Canada Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 07: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 09: U.K. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 10: Germany Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016-2026
Table 11: France Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 12: Italy Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 13: Spain Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 14: Rest of Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 15: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 17: India Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 18: China Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 19: ASEAN Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 20: Rest of Asia Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 21: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 23: Brazil Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 24: Mexico Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 25: Rest of Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 26: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 28: South Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 29: GCC Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 30: Rest of Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
List of Figures
FIG 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, 2016–2026
FIG 02: Global Thalassemia Treatment Market Value Share, by Region (2017)
FIG 03: Global Thalassemia Treatment Market Value Share, by Treatment Type (2017)
FIG 04: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 05: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Transfusion, 2017–2026
FIG 06: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chelating Therapy, 2017–2026
FIG 07: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Bone Marrow Transplant, 2017–2026
FIG 08: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2026
FIG 09: Global Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 10: Global Thalassemia Treatment Market Value Share, by Region, 2018 and 2026
FIG 11: Global Thalassemia Treatment Market Attractiveness, by Region, 2018–2026
FIG 12: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 13: North America Thalassemia Treatment Market Value Share, by Country, 2018–2026
FIG 14: North America Thalassemia Treatment Market Attractiveness, by Country, 2018–2026
FIG 15: North America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 16: North America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 17: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 18: Europe Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 19: Europe Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 20: Europe Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 21: Europe Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 22: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
FIG 23: Asia Pacific Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 24: Asia Pacific Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 25: Asia Pacific Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 26: Asia Pacific Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 27: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
FIG 28: Latin America Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 29: Latin America Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 30: Latin America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 31: Latin America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 32: Middle east & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 33: Middle East & Africa Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 34: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 35: Middle East & Africa Thalassemia Treatment Market Value Share, by Treatment Type , 2018 and 2026
FIG 36: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 37: Global Thalassemia Treatment Market Performance, by Company, 2017
FIG 38: bluebird bio, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 39: bluebird bio, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 40: bluebird bio, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
FIG 41: bluebird bio, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 42: Acceleron Pharma, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 43: Acceleron Pharma, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 44: Acceleron Pharma, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
FIG 45: Acceleron Pharma, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 46: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 47: Novartis AG, Research & Development (US$ Mn) and Marketing & Sales (US$ Mn)– Company Level, 2016–2017
FIG 48: Novartis AG, Net Sales (%), by Oncology Business Units, 2017
FIG 49: Novartis AG, Net Sales (%), by Business Segment, 2017
FIG 50: Incyte Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 51: Incyte Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 52: Incyte Corporation, Breakdown of Revenue Generation (US$ Mn), by Royalties, 2014-2017
FIG 53: Incyte Corporation, Breakdown of Sales (%), by Products, 2017
FIG 54: Kiadis Pharma, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 55: Kiadis Pharma, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 56: Kiadis Pharma, Breakdown of Revenue Generation (US$ Mn), by Operating and Investing Activities, 2016-2017
FIG 57: Kiadis Pharma, Breakdown of Operating Cost to Company (%), 2016 and 2017
FIG 58: Shire plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 59: Shire plc, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 60: Shire plc, Breakdown of Revenue Generation (%), by Region/Country, 2017
FIG 61: Shire plc, Breakdown of Product Sales to Company (%), 2017
FIG 62: Celgene Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 63: Celgene Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 64: Celgene Corporation, Breakdown of Revenue Generation (US$ Mn), by Region, 2015-2017
FIG 65: Celgene Corporation, Net Sales(%), by Products, 2017
FIG 66: Bellicum Pharmaceuticals, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 67: Bellicum Pharmaceuticals, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 68: Bellicum Pharmaceuticals, Breakdown of Revenue Expenses (US$ Mn), by Collaboration and License Agreement, 2014-2017
FIG 69: Bellicum Pharmaceuticals, Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 70: GlaxoSmithKline Plc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 71: GlaxoSmithKline Plc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 72: GlaxoSmithKline Plc., Breakdown of Revenue Generation (US$ Mn), by Products, 2014-2017
FIG 73: GlaxoSmithKline Plc., Breakdown of Sales(%), by Region, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes